Investor Relations

Who is BrainsWay?

BrainsWay is a commercial stage medical device company focused on the development and sale of non-invasive neurostimulation products using the Company’s proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology.

The Company received marketing authorization from the U.S. Food and Drug Administration (FDA) for its products for a variety of patient populations, including in 2013 for patients with major depressive disorder (MDD), in 2018 for patients with obsessive-compulsive disorder (OCD), and in 2020 for patients with smoking addiction.

BrainsWay is currently conducting clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders.

Latest Releases

May 6, 2021

BrainsWay to Report First Quarter 2021 Financial Results on May 20, 2021

CRESSKILL, N.J. and JERUSALEM, Israel, May 06, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in the advanced noninvasive treatment of brain disorders, today announced that it will report its first quarter 2021 financial results as well

Read More

May 5, 2021

BrainsWay Announces Appointment of R. Scott Areglado as Senior Vice President and Chief Financial Officer

CRESSKILL, N.J. and JERUSALEM, May 05, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd. (NASDAQ & TASE: BWAY) (“BrainsWay” or the “Company”), a global leader in advanced noninvasive neurostimulation treatments for mental health disorders, today announced the appointment of R.

Read More

May 4, 2021

BrainsWay Announces Social Media Sweepstakes to Celebrate Mental Health Awareness Month

The Sweepstakes, demonstrating how Deep Transcranial Magnetic Stimulation (Deep TMS) can fit into an average day, offers participants a chance to be one of 20 winners who will receive a curated self-care package CRESSKILL, N.J., May 04, 2021 (GLOBE NEWSWIRE) -- BrainsWay Ltd .

Read More

For more information please contact:

Tel: +1-844-386-7001
Tel: +972-2-647-6010